Emerging drugs for conjunctivitis

Expert Opinion on Emerging Drugs

Volumn 14, Issue 3, 2009, Pages 523-536

  Origlieri, Catherine ^a   Bielory, Leonard ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Allergic; Bacterial; Conjunctivitis; Dry eye; Infectious; Noninfectious; Tear film dysfunction; Treatment; Viral

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACICLOVIR; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZASITE EXTRA; AZASITE PLUS; AZITHROMYCIN; BESIFLOXACIN HYDROCHLORIDE; CEFTRIAXONE; CORTICOSTEROID; CYCLOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMMUNOLOGIC AGENT; IMMUNOMODULATING AGENT; ISV 403; ISV 502; KETOROLAC; KETOTIFEN; MAST CELL STABILIZER; N CHLOROTAURINE; OLOPATADINE; PLACEBO; POLYTRIM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; STEROID; SULFACETAMIDE; TAURINE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ADENOVIRUS; ALLERGIC CONJUNCTIVITIS; APPLICATION SITE BURNING; BLEPHARITIS; BLEPHAROCONJUNCTIVITIS; CATARACT; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CORNEA PERFORATION; CORNEA ULCER; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG MARKETING; EYE INFECTION; GIANT PAPILLARY CONJUNCTIVITIS; GONOCOCCAL CONJUNCTIVITIS; HAEMOPHILUS INFLUENZAE; HERPES SIMPLEX VIRUS; HUMAN; INTRAOCULAR PRESSURE; KERATOPATHY; LACRIMAL GLAND DISEASE; NEISSERIA GONORRHOEAE; NONHUMAN; PERENNIAL ALLERGIC CONJUNCTIVITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOCONJUNCTIVITIS; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC THERAPY; TEAR FILM DYSFUNCTION; TRACHOMA; TRADITIONAL MEDICINE; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VERNAL CONJUNCTIVITIS; VIRAL CONJUNCTIVITIS; VISUAL IMPAIRMENT;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CONJUNCTIVITIS; CONJUNCTIVITIS, BACTERIAL; DRUG DISCOVERY; DRUG INDUSTRY; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOLOGIC FACTORS; THIAZOLIDINEDIONES;

EID: 69949153813     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903103818     Document Type: Review

References (107)

1. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001;51(467):473-477 (Pubitemid 32509650)
2. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86(1):5-17
3. Mahmood AR, Narang AT. Diagnosis and management of the acute red eye. Emerg Med Clin North Am 2008;26(1):35-55, vi
4. Mueller JB, Mcstay CM. Ocular infection and inflammation. Emerg Med Clin North Am 2008;26(1):57-72, vi
5. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005;55(521):962-964 (Pubitemid 41763127)
6. Wagner RS, Aquino M. Pediatric ocular inflammation. Immunol Allergy Clin North Am 2008;28(1):169-88, vii
7. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 2007;98(2):105-14; quiz 14-7, 52 (Pubitemid 46214214)
8. Conjunctivitis Preferred Practice Pattern. American Academy of Ophthalmology, 2008; Available from: http://one.aao.org/Assets/ShowAsset.aspx? id=70977954-f688- 41e3-a009-d2beb86765a9&filename=Conjunctivitis. pdf&aurl=%2fasset. axd%3fid%3d70977954-f688-41e3-a009-d2beb86765a9 [Cited 19 April 2009]
9. Wright HR, Turner A, Taylor HR. Trachoma. Lancet 2008;371(9628):1945-1954
10. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009;93(5):563-568
11. Kalayoglu MV, Pavan-Langston D, Miller JW. Treatment of chlamydial eye infections. Int Ophthalmol Clin 2004 Summer;44(3):135-146
12. Khan BF, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int Ophthalmol Clin 2004 Summer;44(3):103-133 (Pubitemid 38955665)
13. Kamoun L. The red eye. Top Emerg Med 2000;22(4):37-51
14. Westerfeld CB, Kazlas M. Pediatric conjunctivitis. Contemp Ophthalmol 2007;6(3):1-6
15. Romanowski EG, Gordon YJ. Update on antiviral treatment of adenoviral ocular infections. Am J Ophthalmol 2008;146(5):635-637
16. Lévêque N, Amine IL, Cartet G, et al. Two outbreaks of acute hemorrhagic conjunctivitis in Africa due to genotype III coxsackievirus A24 variant. Eur J Clin Microbiol Infect Dis 2006;26:199-202 (Pubitemid 46723490)
17. Teoh DL, Reynolds S. Diagnosis and management of pediatric conjunctivitis. Pediatr Emerg Care 2003;19(1):48-55
18. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):43-58, vi • Provides a broad understanding of the pathophysiology and treatment of SAC and PAC.
19. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 2008;28(1):189-224, vii
20. Woodward DF, Nieves AL, Friedlaender MH. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J Pharmacol Exp Ther 1996;279(1):137-142
21. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3(5):541-553
22. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24(5):331-337 (Pubitemid 37414434)
23. Scadding GK, Keith PK. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother 2008;9(15):2707-2715 • A meta-analysis showing the positive effects of intranasal fluticasone furoate on allergic ocular and nasal symptoms.
24. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008;100(3):272-279 • A meta-analysis illustrating a decrease in allergic eye symptoms with intranasal mometasone furoate.
25. Origlieri C, Bielory L. Intranasal corticosteroids and allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2008;8(5):450-456
26. Mongia A, Bielory L. 677 The Efficacy of Immunotherapy (IT) in Treatment of Allergic Conjunctivitis (AC): a Meta-Analysis. J Allergy Clin Immunol 2003;111(2 part 2):S237
27. Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002;2(5):447-452 (Pubitemid 35239528)
28. Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):59-82, vi • Discusses the rare but severe condition VKC in depth.
29. Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am 2008;28(1):1-23, v
30. Doan S, Chang P, Hoang-Xua T. Conjunctival and lid inflammation in children. Contemp Ophthalmol 2009;8(2):1-8
31. Bielory L. Allergic diseases of the eye. Med Clin North Am 2006;90(1):129-148
32. Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):83-103, vi • Comprehensively covers the pathophysiology, diagnosis, and treatment of GPC.
33. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006;25(8):900-907 •• Current information on TFD as understood by an international expert panel sponsored by the Wilmer Eye Institute. (Pubitemid 44763848)
34. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146(3):350-356 • Discusses the etiology and treatment of TFD.
35. Bielory L. Ocular allergy and dry eye syndrome. Curr Opin Allergy Clin Immunol 2004;4(5):421-424 (Pubitemid 39274084)
36. Foulks GN. The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol 2007;52(4):369-374 • A concise review that discusses the pathophysiology of TFD.
37. Katelaris CH, Bielory L. Evidence-based study design in ocular allergy trials. Curr Opin Allergy Clin Immunol 2008;8(5):484-488
38. Bielory L, Katelaris CH, Lightman S, et al. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 2007;9(3):35 (Pubitemid 47263998)
39. Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11(1):17-33 (Pubitemid 38367076)
40. Smith AF, Pitt AD, Rodruiguez AE, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12(4):233-242
41. Clegg JP, Guest JF, Lehman A, et al. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol 2006;13(4):263-274 (Pubitemid 44180007)
42. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004;23(8):751-761 (Pubitemid 39447303)
43. Hirsch JD, Morello C, Singh R, et al. Pharmacoeconomics of new medications for common chronic ophthalmic diseases. Surv Ophthalmol 2007;52(6):618-633 (Pubitemid 350103882)
44. Engler RJ, Silvers WS, Bielory L. Complementary and alternative medicine education: Need for expanded educational resources for American academy of allergy, asthma & immunology members. J Allergy Clin Immunol 2009;123(2):511-512
45. Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol 2009;123(2):283-94; quiz 95-96 •• A comprehensive analysis of the effects of various CAM modalities on allergic conjunctivitis.
46. Irani AM. Ocular mast cells and mediators. Immunol Allergy Clin North Am 2008;28(1):25-42, v
47. Baroody FM, Foster KA, Markaryan A, et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008;100(3):194-199
48. Naclerio RM, Pinto J, Detineo M, et al. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc 2008;29(1):24-28
49. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol 2000;106(6):1019-1032 (Pubitemid 32006253)
50. Pharmaprojects drug profile: N-chlorotaurine (01 July 2008). Informa UK Ltd., 2008
51. Pharmaprojects drug profile: N-chlorotaurine (03 October 2008). Informa UK Ltd., 2008
52. Products: N-Chlorotaurine. Pathogenics Inc., 2005-2008; Available from: http://www.pathogenics.com/Products/ [Cited 8 April 2009]
53. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis - a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 2005;21(2):157-165 (Pubitemid 40577971)
54. Nagl M, Teuchner B, Pottinger E, et al. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis - a phase II pilot study. Ophthalmologica 2000;214(2):111-114 (Pubitemid 30179204)
55. Pharmaprojects drug profile: ISV-403 (01 July 2008). Informa UK Ltd., 2008
56. Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli [abstract]. J Antimicrob Chemother 2009;63(3):443-450
57. Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother 2008;61(1):111-116
58. Pharmaprojects drug profile: AsaSite (01 July 2008). Informa UK Ltd., 2008
59. Protzko E, Bowman L, Abelson M, et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48(8):3425-3429 (Pubitemid 351261073)
60. Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis. U.S. National Institutes of Health, 2007; Available from: http://clinicaltrials.gov/ct2/show/ NCT005 78955?term=NCT00578955&rank=1 [Cited 8 April 2009]
61. Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis. U.S. National Institutes of Health, 2008; Available from: http://clinicaltrials.gov/ct2/show/ NCT007 54949?term=NCT00754949&rank=1 [Cited 8 April 2009]
62. Pharmaprojects drug profile: Bepotastine (01 July 2008). Informa UK Ltd., 2008
63. Pharmaprojects drug profile: Bepotastine (03 October 2008). Informa UK Ltd., 2008
64. Products: Bepotastine. ISTA Pharmaceuticals, 2009; Available from: http://www.istavision.com/research/products-bepotastine.asp# [Cited 13 April 2009]
65. Macejko TT, Meier EJ, Bergmann MT, et al. Bepotastine besilate ophthalmic solution 1.5% for up to 8 hours following dosing reduces total non-ocular symptoms, rhinorrhea, and tearing in a multi-site clinical model of allergic conjunctivitis. AAAAI Annual Meeting, 13-17 March; 2009; Washington, D.C. J Allergy Clin Immunol 2009;123(2):S57
66. Meier EJ, Macejko TT, Bergmann MT, et al. Bepotastine besilate ophthalmic solution 1.0% provides rapid relief of rhinorrhea, total non-ocular symptoms, tearing, and ciliary and episcleral hyperemia following dosing in a multi-site clinical model of allergic conjunctivitis [abstract]. AAAAI Annual Meeting, 13-17 March; 2009; Washington, D.C. J Allergy Clin Immunol 2009;123(2):S57
67. Torkildsen GL, Gomes PJ, Williams JI, et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a clinical model of allergic conjunctivitis. AAAAI Annual Meeting, 13-17 March; 2009; Washington, D.C. J Allergy Clin Immunol 2009;123(2):S57
68. ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration. ISTA Pharmaceuticals, 2009; Available from: http://phx. corporate-ir.net/phoenix. zhtml?c=121179&p=irol- newsArticle&ID =1244943&highlight=bepotastine [Cited 13 April 2009]
69. Pharmaprojects drug profile: Bromfenac (01 July 2008). Informa UK Ltd., 2008
70. Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis. U.S. National Institutes of Health, 2007; Available from: http://clinicaltrials.gov/ct2/ show/NCT00423007?term= NCT0042300 7&rank=1 [Cited 14 April 2009]
71. Products: Xibrom QD. ISTA Pharmaceuticals, 2009; Available from: http://www.istavision.com/research/products-XibromQD.asp [Cited 14 April 2009]
72. Pharmaprojects drug profile: Ibudilast (03 October 2008). Informa UK Ltd., 2008
73. Huang Z, Liu S, Zhang L, et al. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci 2006;78(23):2663-2668
74. Tsukioka A. Kyorin Pharmaceutical, MedicNova Conclude Licensing Agreement for Ibudilast. Japan's Corporate News Network, 2009; Available from: http://www.japancorp.net/Article.Asp?Art-ID=8629 [Cited 14 April 2009]
75. Pharmaprojects drug profile: DE-103 (01 July 2008). Informa UK Ltd., 2008
76. Pipeline of prescription pharmaceuticals. Santen Pharmaceutical Co., Ltd., 2006; Available from: http://www.santen.com/ir/reports/ktref20080130-02. pdf [Cited 16 April 2009]
77. Pharmaprojects drug profile: FOV-1101 (03 October 2008). Informa UK Ltd., 2008
78. Fovea's Pipeline. Fovea Pharmaceuticals; Available from: http://www.fovea-pharma. com/drug3.htm [Cited 14 April 2009]
79. Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation. U.S. National Institutes of Health, 2009; Available from: http://clinicaltrials.gov/ ct2/show/NCT008 33495?term=NCT00833495&rank=1 [Cited 14 April 2009]
80. Pharmaprojects drug profile: CYT005-AllQbG10 (01 July 2008). Informa UK Ltd., 2008
81. Pharmaprojects drug profile: CYT005-AllQbG10 (03 October 2008). Informa UK Ltd., 2008
82. CYT003-QbG10 a Novel Immunotherapy for Allergies. Cytos Biotechnology, 2008; Available from: http://www.cytos.com/userfiles/file/QbG10-Facts-0908.pdf [Cited 15 April 2009]
83. Vaccine candidate CYT005-AllQbG10 for allergic diseases shows significant efficacy in phase IIa study. Cytos Biotechnology, 2005; Available from: http://www.cytos.com/doc/Cytos-PhaseIIa-E-051214.pdf [Cited 15 April 2009]
84. CYT003-QbG10 monotherapy for the treatment of allergic diseases is safe and efficacious in placebo-controlled phase II study. Cytos Biotechnology, 2008; Available from: http://www.cytos.com/userfiles/file/Cytos-Press-E-080710.pdf [Cited 15 April 2009]
85. Clinical trial advances Cytos Biotechnology's second Immunodrug(TM) platform. Cytos Biotechnology, 2004; Available from: http://www.cytos.com/doc/ Cytos-QbG10-E.pdf [Cited 15 April 2009]
86. Placebo-controlled phase IIa study with the immunotherapeutic CYT003-QbG10 shows significant improvement of allergy symptoms in hay fever patients. Cytos Biotechnology, 2007; Available from: http://www.cytos.com/doc/ Cytos-Press-E-070313.pdf [Cited 15 April 2009]
87. CYT003-QbG10, a novel allergen-independent immunotherapy for allergic diseases, achieves significant efficacy in phase IIa pilot study. Cytos Biotechnology, 2006; Available from: http://www.cytos.com/doc/Cytos-Press-E- 060920.pdf [Cited 15 April 2009]
88. Cytos Biotechnology reports positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy. Cytos Biotechnology, 2007; Available from: http://www.cytos.com/doc/Cytos-Press-E- 070515.pdf [Cited 15 April 2009]
89. Cytos Biotechnology presents analysis of patient diaries including six month follow-up data from phase II study with CYT003-QbG10 monotherapy for the treatment of allergic diseases. Cytos Biotechnology, 2009; Available from: http://www.cytos.com/userfiles/file/Cytos-Press-E-090113.pdf [Cited 15 April 2009]
90. Leonardi A. In-vivo diagnostic measurements of ocular inflammation. Curr Opin Allergy Clin Immunol 2005;5(5):464-472 (Pubitemid 41345318)
91. Leonardi A, Curnow SJ, Zhan H, et al. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006;36(6):777-784 (Pubitemid 43972973)
92. Leonardi A, Jose PJ, Zhan H, et al. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003;110(3):487-492 (Pubitemid 36262729)
93. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115(1):118-122
94. Pharmaprojects drug profile: Bertilimumab (01 July 2008). Informa UK Ltd., 2008
95. Pharmaprojects drug profile: Bertilimumab (03 October 2008). Informa UK Ltd., 2008
96. Pipeline: iCo-008. iCo Therapeutics Inc., 2005; Available from: http://www. icotherapeutics.com/site/pipeline/ico008/ [Cited 15 April 2009]
97. Pharmaprojects drug profile: Tacrolimus (01 July 2008). Informa UK Ltd., 2008
98. Talymus Ophthalmic Suspension 0.1%. ClinicalStudyResults.org, 2009; Available from: http://www.clinicalstudyresults.org/ drugdetails/viewfile.php? study-name=FJ-506D-AC09+Summary&file=%2Fdocuments%2Fcompany-study-8768-0. pdf [Cited 16 April 2009]
99. Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis. U.S. National Institutes of Health, 2007; Available from: http://clinicaltrials.gov/ct2/show/NCT005 67762?term=NCT00567762&rank=1 [Cited 15 April 2009]
100. Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis. U.S. National Institutes of Health, 2007; Available from: http://clinicaltrials.gov/ct2/show/NCT005 67918?term=NCT00567918&rank=1 [Cited 15 April 2009]
101. Joseph MA, Kaufman HE, Insler M. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24(4):417-420 (Pubitemid 40586629)
102. Virtanen HM, Reitamo S, Kari M, et al. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006;84(5):693-695 (Pubitemid 44317552)
103. Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study. U.S. National Institutes of Health, 2007; Available from: http://clinicaltrials.gov/ct2/show/NCT004 43105?term=NCT00443105&rank=1 [Cited 15 April 2009]
104. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004;113(2):355-358 (Pubitemid 38210564)
105. Sucampo Pharmaceuticals Begins Phase II Study for Treatment of Dry Eye Syndrome with Agent FK-506 (Tacrolimus). Sucampo Pharmaceuticals, Inc.; Available from: http://investor.sucampo. com/phoenix.zhtml?c=201197&p= irolnewsArticle& ID=936536&highlight [Cited 15 April 2009]
106. Pharmaprojects drug profile: Rivoglitazone (03 October 2008). Informa UK Ltd., 2008
107. Chang F, Jaber LA, Berlie HD, et al. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007;41(6):973-983